

PRODUCT MONOGRAPH

<sup>Pr</sup>**MYLAN-TAMOXIFEN**

Tamoxifen Citrate Tablets, BP

**10 mg and 20 mg tamoxifen (as tamoxifen citrate)**

Antineoplastic Agent

MYLAN PHARMACEUTICALS ULC  
85 Advance Road  
Etobicoke, Ontario  
M8Z 2S6

Date of Revision:  
February 6, 2014

Control No.: 171511

## NAME OF DRUG

Pr **MYLAN-TAMOXIFEN**

(Tamoxifen Citrate Tablets, BP)

10 mg and 20 mg tamoxifen (as tamoxifen citrate)

## THERAPEUTIC CLASSIFICATION

Antineoplastic Agent (non-steroidal antiestrogen)

**Tamoxifen citrate therapy was associated with serious and life-threatening events including uterine malignancies, stroke, pulmonary embolism, and deep vein thrombosis in the NSABP P-1 trial for the prevention of breast cancer. The use of tamoxifen citrate for breast cancer prevention is not an approved indication in Canada. In the NSABP P-1 trial, the relative risk of tamoxifen citrate compared to placebo was 3.1 for endometrial cancer, 4.0 for uterine sarcomas, 1.6 for stroke, 3.0 for pulmonary embolism, and 1.6 for deep vein thrombosis. These events were fatal in some patients. Health care providers should be aware of the possible risks associated with tamoxifen citrate therapy and should discuss them with their patients.**

**THE BENEFITS OF TAMOXIFEN CITRATE THERAPY OUTWEIGH THE RISKS IN THE MAJORITY OF WOMEN BEING TREATED ACCORDING TO THE APPROVED CANADIAN INDICATION FOR THE TREATMENT OF BREAST CANCER.**

## ACTIONS AND CLINICAL PHARMACOLOGY

Tamoxifen citrate, the active ingredient, is a non-steroidal agent which has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects are related to its ability to compete with estrogen for binding sites in target tissues such as breast and uterus. Tamoxifen citrate inhibits the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA-induced tumours. In this rat model, tamoxifen citrate appears to exert its antitumour effects by binding to estrogen receptors.

In cytosols derived from human endometrium and human breast and uterine adenocarcinomas, tamoxifen competes with estradiol for estrogen receptor protein.

In women with estrogen receptor-positive/unknown breast tumours, adjuvant tamoxifen citrate has been shown to significantly reduce recurrence of the disease and improve 10-year survival, achieving a significantly greater effect with five years treatment than with one or two years treatment. These benefits appear to be largely irrespective of age, menopausal status, tamoxifen citrate dose and additional chemotherapy.

Ranges as large as 0-300 fmol/mg protein have been reported in histologically comparable portions of the same tumour. In addition, the collection, transport and storage of tumour specimens can affect the validity of current estrogen receptor assays.

The apparent discrepancy in correlation between estrogen receptor status and clinical response may also be explained by recent *in vitro* evidence indicating that not all of the growth inhibiting effects of tamoxifen citrate are mediated through the estrogen receptor. Tamoxifen citrate has been shown to have a low affinity for the androgen receptor and on a binding site distinct from the estrogen receptor. The possibility also exists that tamoxifen citrate interferes with the action of hormonal steroids on cell growth, that it could modulate the action of peptide hormones at their receptors by effects on cell membranes, and that it inhibits prostaglandin synthetase thereby having the potential to limit tumour growth. It is recognized that tamoxifen citrate also displays estrogenic-like effects on several body systems including the endometrium, bone and blood lipids.

### **INDICATIONS**

MYLAN-TAMOXIFEN (tamoxifen citrate) is indicated for the adjuvant treatment of early breast cancer in women with estrogen receptor positive tumours.

MYLAN-TAMOXIFEN is indicated for the treatment of women with hormone responsive locally advanced/ metastatic breast cancer.

### **CONTRAINDICATIONS**

MYLAN-TAMOXIFEN (tamoxifen citrate) is contraindicated in patients with hypersensitivity to the product or any of its components.

MYLAN-TAMOXIFEN must not be given during pregnancy. There have been a small number of reports of spontaneous abortions, birth defects and fetal deaths after women have taken tamoxifen citrate, although no causal relationship has been established.

Reproductive toxicology studies in rats, rabbits and monkeys have shown no teratogenic potential.

In rodent models of fetal reproductive tract development, tamoxifen was associated with changes similar to those caused by estradiol, ethynylestradiol, clomiphene and diethylstilboestrol (DES). Although the clinical relevance of these changes is unknown, some of them, especially vaginal adenosis, are similar to those seen in young women who were exposed to DES *in utero* and who have a 1 in 1000 risk of developing clear-cell carcinoma of the vagina or cervix. Only a small number of pregnant women have been exposed to tamoxifen citrate. Such exposure has not been reported to cause subsequent vaginal adenosis or clear-cell carcinoma of the vagina or cervix in young women exposed *in utero* to tamoxifen citrate.

Women should be advised not to become pregnant while taking MYLAN-TAMOXIFEN and should use barrier or other non-hormonal contraceptive methods if sexually active. Pre-menopausal patients must be carefully examined before treatment to exclude the possibility of pregnancy. Women should be informed of the potential risks to the fetus, should they become pregnant while taking MYLAN-TAMOXIFEN or within two months of cessation of therapy.

When used in the prevention setting (an indication not approved in Canada), MYLAN-TAMOXIFEN is contraindicated in patients with a history of stroke, deep venous thrombosis or pulmonary embolism, and in patients who are at an increased risk of developing endometrial cancer.

### **WARNINGS**

MYLAN-TAMOXIFEN (tamoxifen citrate) should be used only for the conditions listed under the INDICATIONS section.

An increased incidence of uterine malignancies has been reported in association with tamoxifen citrate treatment. The underlying mechanism is unknown, but may be related to the estrogen-like effect of tamoxifen citrate. Most uterine malignancies seen in association with tamoxifen citrate are classified as adenocarcinoma of the endometrium. However, rare uterine sarcomas, including malignant mixed Mullerian tumours, have also been reported. Uterine sarcoma is generally associated with a higher FIGO stage (III/IV) at diagnosis, poorer prognosis, and shorter survival. Uterine sarcoma has been reported to occur more frequently among long-term users ( $\geq 2$  years) of tamoxifen citrate than non-users.

There is evidence of an increased incidence of thromboembolic events, including deep vein thrombosis and pulmonary embolism, occurring commonly during tamoxifen citrate therapy (see ADVERSE REACTIONS). When tamoxifen citrate is co-administered with chemotherapy, there may be a further increase in the incidence of thromboembolic effects. For treatment of breast cancer, the risks and benefits of MYLAN-TAMOXIFEN should be carefully considered in women with a history of thromboembolic events.

An increased risk of stroke has been found to be associated with tamoxifen citrate therapy in high-risk patients being treated for the prevention of breast cancer. The use of MYLAN-TAMOXIFEN for the prevention of breast cancer is not an approved indication in Canada.

Incidence rates for the following events were estimated from a long-term clinical study called the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention (NSABP P-1) Trial. In this trial, high-risk patients were randomized to either tamoxifen citrate therapy or placebo, for the prevention of breast cancer. Uterine malignancies were separated into cases of endometrial adenocarcinomas and uterine sarcomas. The relative risk of tamoxifen citrate compared to placebo was 3.1 for endometrial cancer, 4.0 for uterine sarcomas, 1.6 for stroke, 3.0 for pulmonary embolism, and 1.6 for deep vein thrombosis.

Disturbances of menstrual function, including oligomenorrhea and amenorrhea, have been reported in a proportion of pre-menopausal women receiving tamoxifen citrate for the

treatment of breast cancer. Available information indicates that in those women receiving tamoxifen citrate for up to two years for the treatment of early breast cancer who develop disturbances of menstrual function on treatment, a proportion return to normal cyclical bleeding on cessation of therapy.

Hepatocellular carcinomas have been reported in a 2 year oncogenicity study in rats receiving tamoxifen citrate (see TOXICOLOGY). In addition, gonadal tumours have been reported in mice receiving tamoxifen citrate in long-term studies (see TOXICOLOGY). The clinical relevance of these cancer findings has not been established.

Cataracts were also reported in the 2-year oncogenicity study in rats, and since then it has been established that treatment with tamoxifen citrate has been associated with an increased incidence of cataracts.

The use of some hormonal agents in breast cancer therapy has been associated with myalgia. Myalgia has been reported in patients receiving tamoxifen citrate in clinical trials and the post-market setting (see ADVERSE REACTIONS). In clinical trials, the incidence of myalgia was similar between patients treated with tamoxifen or an aromatase inhibitor reported to be associated with this event. In post-market reports, discontinuation of treatment resulted in resolution of symptoms.

A number of second primary tumours, occurring at sites other than the endometrium and the opposite breast, have been reported in clinical trials, following the treatment of breast cancer patients with tamoxifen citrate. No causal link has been established and the clinical significance of these observations remains unclear.

As tamoxifen citrate has been associated with increased rates of thromboembolic events, MYLAN-TAMOXIFEN may increase the risk of complications after microvascular breast reconstruction. A retrospective study found that women taking tamoxifen citrate within 28 days of undergoing delayed breast reconstruction had a higher rate of complications (21.5%), including total flap loss (3.9%), compared to women who had not received tamoxifen citrate within 28 days of surgery (15% and 0.4%, respectively). Of the total flap losses, 90% were due to either venous or arterial thrombosis. Consideration should be given to temporarily interrupt MYLAN-TAMOXIFEN before undergoing delayed microvascular breast reconstruction after a careful individual benefit/risk assessment.

MYLAN-TAMOXIFEN is a pro-drug requiring metabolic activation by CYP2D6. Low CYP2D6 activity that occurs in patients harbouring certain CYP2D6 alleles (*i.e.* \*4) or from the chronic use of CYP2D6 inhibitors can lead to persistent reductions in plasma concentrations of an active metabolite of tamoxifen citrate (endoxifen). Reduced efficacy on tamoxifen citrate has been reported with concomitant usage of some selective serotonin reuptake inhibitor (SSRI) antidepressants (e.g. paroxetine, a known CYP2D6 inhibitor). Concurrent chronic use of CYP2D6 inhibitors that may affect tamoxifen citrate efficacy should be avoided if possible (see also PRECAUTIONS, Drug Interactions).

## **PRECAUTIONS**

MYLAN-TAMOXIFEN (tamoxifen citrate) should be used cautiously in patients with existing thrombocytopenia or leukopenia. Decreases in platelet counts, usually to 80,000-90,000/mm<sup>3</sup>, infrequently lower, have been observed occasionally during treatment with tamoxifen citrate. However, no hemorrhagic tendency has been reported, and the platelet counts returned to normal levels even though treatment with tamoxifen citrate was continued.

Transient decreases in leukocytes also have been observed occasionally during treatment. Although it was uncertain if these occasional incidences of leukopenia and thrombocytopenia were due to tamoxifen citrate therapy, complete blood counts, including platelet counts, should be obtained periodically.

As with other additive hormonal therapy (estrogens and androgens), hypocalcaemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen citrate. Any symptoms suggestive of hypocalcaemia should be evaluated promptly. Patients who have metastatic bone disease should have periodic serum calcium determinations during the first few weeks of tamoxifen citrate therapy. If hypocalcaemia is present, appropriate measures should be taken and, if severe, MYLAN-TAMOXIFEN should be discontinued.

The first patient follow-up should be done within one month following initiation of treatment. Thereafter, examinations may be performed at one to two-month intervals.

Bone pain, if it should occur, may require the use of analgesics.

An increased incidence of endometrial cancer and uterine sarcoma (mostly malignant mixed Mullerian tumours) has been reported in association with tamoxifen citrate treatment. The incidence and pattern of this increase suggest that the underlying mechanism may be related to estrogenic properties of tamoxifen citrate. Any patients receiving MYLAN-TAMOXIFEN or having previously received MYLAN-TAMOXIFEN who report abnormal gynaecological symptoms, especially vaginal bleeding, should be promptly investigated.

In clinical studies, the median duration of treatment before the onset of a definite objective response has been two months. However, approximately one-quarter of patients who eventually responded were treated for four or more months before a definite objective response was recorded.

The duration of treatment with MYLAN-TAMOXIFEN will depend on the patient's response. The drug should be continued as long as there is a favourable response (see DOSAGE AND ADMINISTRATION).

With obvious disease progression, the drug should be discontinued. However, because an occasional patient will have a local disease flare (see description under ADVERSE REACTIONS) or an increase in bone pain shortly after starting tamoxifen citrate, it is sometimes difficult during the first few weeks of treatment to determine whether the patient's disease is

progressing or whether it will stabilize or respond to continued treatment. There are data to suggest that, if possible, treatment should not be discontinued before a minimum of three to four weeks.

### ***Drug Interactions***

When tamoxifen citrate is used in combination with coumarin-type anticoagulants, a significant increase in anticoagulant effect may occur. Where such co-administration exists, careful monitoring of the patient's prothrombin time is recommended.

When tamoxifen citrate is used in combination with cytotoxic agents, there is increased risk of thromboembolic events occurring.

The use of tamoxifen citrate in combination with an aromatase inhibitor as adjuvant therapy has not shown improved efficacy compared with tamoxifen citrate alone.

The known principal pathway for tamoxifen citrate metabolism in humans is demethylation, catalyzed by CYP3A4 enzymes. A pharmacokinetic interaction with the CYP3A4 inducing agent rifampicin, involving a reduction in tamoxifen citrate plasma levels has been reported in the literature. The relevance of this to clinical practice is not known.

Pharmacokinetic interaction with CYP2D6 inhibitors, showing a reduction in plasma level of an active tamoxifen citrate metabolite, 4-hydroxy-N-desmethyltamoxifen (endoxifen), has been reported in the literature. Chronic use of CYP2D6 inhibitors can lead to reduced plasma concentrations of an active metabolite. Reduced efficacy on tamoxifen citrate has been reported with concomitant usage of some SSRI antidepressants (e.g. paroxetine) (see WARNINGS).

### **Pediatric Use:**

The use of MYLAN-TAMOXIFEN is not recommended in children, as safety and efficacy have not been established.

### **Nursing Mothers**

It is not known if tamoxifen citrate is excreted in human milk and, therefore, the drug is not recommended during lactation. The decision either to discontinue nursing or discontinue MYLAN-TAMOXIFEN should take into account the importance of the drug to the mother.

### **Effect on Ability to Drive and Use Machinery**

MYLAN-TAMOXIFEN is unlikely to impair the ability of patients to drive or operate machinery. However, fatigue and asthenia have been reported with the use of tamoxifen and caution should be observed when driving or operating machinery while such symptoms persist.

## **ADVERSE REACTIONS**

Side effects can be classified as either due to the pharmacological action of the drug, e.g., hot flushes, vaginal discharge, pruritus vulvae, or those requiring further investigations, such as vaginal bleeding (to exclude the possibility of endometrial malignancy) and tumour flare (to exclude the possibility of progressive disease). Side effects can also be classified as more general in nature such as gastrointestinal intolerance (including such events as nausea, vomiting, constipation and diarrhea), headache, light-headedness and occasionally fluid retention and

alopecia. When such side effects are severe, it may be possible to control them by a simple reduction of dosage (within the recommended dose range) without loss of control of the disease. Skin rashes (including rare reports of erythema multiforme, Stevens-Johnson syndrome, cutaneous vasculitis, and bullous pemphigoid) and commonly, hypersensitivity reactions, including angioedema, have been reported.

Increased bone and tumour pain and also local disease flare have occurred. These are sometimes associated with a good tumour response. Patients with soft tissue disease may have sudden increases in the size of pre-existing lesions, sometimes associated with marked erythema within and surrounding the lesions, and/or the development of new lesions. When they occur, the bone pain or disease flare are seen shortly after starting tamoxifen citrate and generally subside rapidly. Uncommonly, patients with bony metastases have developed hypercalcaemia on initiation of therapy (see PRECAUTIONS).

Cataracts and retinopathy have been commonly reported in association with the administration of tamoxifen citrate (see WARNINGS). Other visual disturbances include retinal crystals, macular edema, keratopathy, and rare reports of corneal changes. Rare cases of optic neuropathy and optic neuritis have been reported in patients receiving tamoxifen and, in a small number of cases, blindness has occurred.

Paraesthesia (tingling, pricking and numbness of skin) has been commonly reported in patients receiving tamoxifen citrate. Dysgeusia (taste loss and perversion) has been uncommonly reported in patients receiving tamoxifen citrate.

Decreases in platelet counts, usually only to 80,000 - 90,000 per cu mm but occasionally lower, have been uncommonly reported in patients taking tamoxifen citrate.

There have been uncommon reports of leucopenia and/or thrombocytopenia, sometimes in association with anaemia. Neutropenia, including cases of agranulocytosis, have also been reported on rare occasions.

There is evidence of an increased incidence of ischemic cerebrovascular and thromboembolic events, including deep vein thrombosis and pulmonary embolism, occurring commonly during tamoxifen citrate therapy (see WARNINGS). An increased incidence of microvascular thrombosis has also been reported in women treated with tamoxifen citrate undergoing delayed microvascular breast reconstruction (see WARNINGS).

In the prevention setting, treatment with tamoxifen citrate has been associated with an increased risk of stroke (see WARNINGS). When tamoxifen citrate is used in combination with cytotoxic agents, there is an increased risk of thromboembolic events occurring.

Myalgia has been reported commonly in patients receiving tamoxifen citrate. In these cases, discontinuation of treatment resulted in resolution of symptoms.

Elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl transpeptidase (GGT) levels have been reported commonly during tamoxifen citrate

therapy. On occasion, severe liver diseases have occurred from which some patients taking tamoxifen have died. Liver abnormalities reported include fatty liver, cholestasis and hepatitis, liver failure, cirrhosis, and hepatocellular injury (including hepatic necrosis). Occasionally, cases of hepatic cyst and peliosis hepatitis have also been reported.

Uncommon incidences of endometrial cancer and rare instances of uterine sarcoma (mostly malignant mixed Mullerian tumours) have been reported in association with tamoxifen citrate treatment (see WARNINGS and PRECAUTIONS).

Cutaneous lupus erythematosus and porphyria cutanea tarda have been observed rarely in patients receiving tamoxifen citrate. In these cases, discontinuation of treatment resulted in resolution of symptoms.

Fatigue and asthenia have been reported very commonly in patients taking tamoxifen.

Other adverse reactions which are seen infrequently are depression and distaste for food.

Unless specified, the following frequency categories were calculated from the number of adverse events reported in the control arm of a large phase III study conducted where 3094 postmenopausal women patients with operable breast cancer were treated for 5 years with tamoxifen citrate and where no account was taken of whether the investigator considered it to be related to the study medication.

**Table 1 Adverse Drug Reactions (ADR) seen with Tamoxifen Citrate\***

<b>Frequency</b>	<b>System Organ Class (SOC)</b>	<b>ADR</b>
<b>Very common (≥10%)</b>	Gastrointestinal disorders	• Nausea
	General disorder and administrative site conditions	• Fatigue/Asthenia
	Metabolism and nutrition	• Fluid retention
	Reproductive system and breast	• Vaginal bleeding
	Skin and subcutaneous tissue	• Vaginal discharge
	Vascular	• Skin Rash
<b>Common (≥1% and &lt;10%)</b>	Blood and lymphatic system	• Hot flushes
	Eye disorders	• Anemia
	Immune system disorders	• Cataracts
	Investigations	• Retinopathy
	Musculoskeletal and connective tissue	• Hypersensitivity reactions
		• Elevated triglycerides
		• Leg cramp

	Neoplasms benign, malignant and unspecified	<ul style="list-style-type: none"> <li>• Myalgia</li> <li>• Uterine fibroids</li> <li>• Tumour Flare<sup>a</sup></li> </ul>
	Nervous system	<ul style="list-style-type: none"> <li>• Ischaemic cerebrovascular events</li> <li>• Headache</li> <li>• Light headedness</li> <li>• Paraesthesia</li> <li>• Pruritus vulvae</li> <li>• Endometrial changes (including hyperplasia and polyps)</li> </ul>
	Reproductive system and breast	<ul style="list-style-type: none"> <li>• Alopecia</li> <li>• Vomiting</li> <li>• Diarrhoea</li> <li>• Constipation</li> <li>• Changes in liver enzymes</li> <li>• Fatty liver</li> <li>• Thromboembolic events (including deep vein thrombosis, microvascular thrombosis and pulmonary embolism)</li> </ul>
	Skin and subcutaneous tissue	
	Gastrointestinal disorders	
	Hepatobiliary disorders	
	Multiple SOC Terms	
	Blood and lymphatic system	<ul style="list-style-type: none"> <li>• Thrombocytopenia</li> <li>• Leucopenia</li> <li>• Pancytopenia</li> <li>• Visual disturbances</li> <li>• Pancreatitis</li> <li>• Hypercalcaemia (in patients with bony metastases)</li> </ul>
	Eye disorders	
	Gastrointestinal disorders	
	Metabolism and nutrition	
	Neoplasms benign, malignant and unspecified	<ul style="list-style-type: none"> <li>• Endometrial cancer</li> <li>• Dysgeusia</li> <li>• Interstitial pneumonitis</li> </ul>
	Nervous system	
	Respiratory, thoracic and mediastinal disorders	
	Hepatobiliary disorders	<ul style="list-style-type: none"> <li>• Cirrhosis of the liver</li> <li>• Neutropenia<sup>a</sup></li> <li>• Agranulocytosis<sup>a</sup></li> <li>• Corneal changes</li> <li>• Optic neuropathy<sup>a</sup></li> </ul>
	Blood and lymphatic system disorders	
	Eye disorders	
<b>Uncommon</b> (≥0.01% and <1%)		
<b>Rare</b> (≥0.01% and <0.1%)		

Neoplasms benign, malignant and unspecified (incl cysts and polyps)	• Uterine Sarcoma (mostly malignant mixed Mullerian tumours) <sup>a</sup>
Reproductive system and breast disorders	• Vaginal polyps <sup>a</sup>
	• Endometriosis <sup>a</sup>
	• Cystic ovarian swelling <sup>a</sup>
Nervous system	• Optic neuritis
Hepatobiliary disorders	• Hepatitis
	• Cholestasis <sup>a</sup>
	• Hepatic failure <sup>a</sup>
	• Hepatocellular injury <sup>a</sup>
	• Hepatic necrosis <sup>a</sup>
Skin and subcutaneous tissue	• Angioedema
	• Steven-Johnsons syndrome <sup>a</sup>
	• Cutaneous vasculitis <sup>a</sup>
	• Bullous pemphigoid <sup>a</sup>
	• Erythema multiforme <sup>a</sup>
Skin and subcutaneous tissue	• Cutaneous lupus erythematosus <sup>b</sup>
Congenital, familial and genetic disorders	• Porphyria cutanea tarda <sup>b</sup>

\* Adverse event rates may not apply to premenopausal women or women treated for locally advanced or metastatic disease.

<sup>a</sup> Exact frequency not known but known to occur at ≤ 0.1% from the ATAC study (A Randomized, Double-Blind Trial Comparing Anastrozole to Tamoxifen).

<sup>b</sup> The event was not observed in other major clinical studies. The frequency has been calculated using the upper limit of the 95% confidence interval for the point estimate (based on 3/X, where X represents the total sample size of 13,357 patients in the major clinical studies). This is calculated as 3/13,357 which equates to a frequency category of 'rare'.

## **SYMPTOMS AND TREATMENT OF OVERDOSAGE**

Acute overdosage in humans has not been reported. Possible overdosage effects might include hot flushes, nausea, vomiting, and vaginal bleeding. No specific treatment for overdosage is known and treatment must be symptomatic.

In the case of accidental ingestion by a child, gastric emptying is suggested.

There have been reports in the literature that tamoxifen citrate given at several times the standard dose may be associated with prolongation of the QT interval of the ECG.

**For management of a suspected drug overdose, contact your regional Poison Control Centre.**

## **DOSAGE AND ADMINISTRATION**

The recommended daily dose of MYLAN-TAMOXIFEN (tamoxifen citrate) is 20 to 40 mg in a single or two divided doses. The lowest effective dose should be used. In early disease, the recommended duration of therapy is 5 years. The optimal duration of therapy remains to be determined.

**Pediatric Use:** The use of MYLAN-TAMOXIFEN is not recommended in children, as safety and efficacy have not been established.

### **AVAILABILITY**

MYLAN-TAMOXIFEN (tamoxifen citrate) tablets 10 mg: White, round, biconvex uncoated tablets containing 15.2 mg tamoxifen citrate, equivalent to 10 mg tamoxifen, marked with "TN" over "10" on one side and "G" on the other; available in bottles of 250 tablets or boxes of 60 tablets in aluminum blister packs. Store at room temperature (15°C to 30°C) protected from light.

MYLAN-TAMOXIFEN (tamoxifen citrate) tablets 20 mg: White, octagonal shaped, biconvex uncoated tablets containing 30.4 mg tamoxifen citrate equivalent to 20 mg tamoxifen, marked with "G" on one side and scored with "TN/20" on the other side; available in bottles of 250 tablets or boxes of 30 tablets in aluminum blister packs. Store at room temperature (15°C to 30°C) protected from light.

## **INFORMATION FOR THE PATIENT**

### **PrMYLAN-TAMOXIFEN**

(Tamoxifen Citrate Tablets, BP)

10 mg and 20 mg tamoxifen (as tamoxifen citrate)

#### **DESCRIPTION**

MYLAN-TAMOXIFEN (tamoxifen citrate) is a medicine that blocks the effects of the hormone estrogen in the body. It is used to treat breast cancer.

The exact way that tamoxifen works against cancer is not known, but it may be related to the way it blocks the effects of estrogen on the body.

MYLAN-TAMOXIFEN is available only with your doctor's prescription.

#### **WHAT DOES MYLAN-TAMOXIFEN CONTAIN?**

In addition to the active ingredient tamoxifen citrate, each tablet contains the following inactive ingredients: mannitol, maize starch, croscarmellose sodium and magnesium stearate.

#### **BEFORE USING THIS MEDICATION**

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make.

Before taking MYLAN-TAMOXIFEN, tell your doctor if any of the following apply to you:

- If you have ever had any unusual or allergic reaction to MYLAN-TAMOXIFEN or to any one of its ingredients (See What Does MYLAN-TAMOXIFEN Contain?).
- If you intend to become pregnant. It is best to use some kind of birth control while you are taking MYLAN-TAMOXIFEN and for about two months after you stop taking it. Please see your doctor for advice on what contraceptive precautions you should take, as some may be affected by MYLAN-TAMOXIFEN. Tell your doctor right away if you think you have become pregnant while taking tamoxifen or within two months of having stopped it.
- It is important that you tell your doctor immediately if you have any unusual vaginal bleeding or other gynaecological symptoms (such as pelvic pain or pressure) when you are taking MYLAN-TAMOXIFEN or anytime afterwards. This is because a number of changes to the lining of the womb (the endometrium) may occur, some of which may be serious and could include cancer.
- If you are breastfeeding or intend to breastfeed.
- If you are taking or have recently taken any other prescription, including antidepressants such as paroxetine (to improve mood or symptoms of hot flushes), or over-the-counter medicine.

- If you have any other medical problems, especially cataracts (or other eye problems) or low blood cell counts.
- If you have a history of blood clots, including deep vein thrombosis (a blood clot in one of the deep veins of the body – usually within the leg) or are taking anticoagulants such as warfarin (to prevent blood clots).
- MYLAN-TAMOXIFEN should not be taken with aromatase inhibitors, such as anastrozole, letrozole or exemestane.
- If you are going to have a breast reconstruction operation where your own tissue is moved to shape a new breast and this occurs weeks to years after the primary cancer operation, MYLAN-TAMOXIFEN may increase your risk of complications, including complete loss of the new tissue.
- If you have a history of pulmonary embolism (obstruction of a pulmonary artery by foreign matter such as fat, air, tumour tissue or a blood clot).
- If you have a history of stroke.
- If you go into the hospital, let medical staff know you are taking MYLAN-TAMOXIFEN.

**YOU SHOULD NOT TAKE MYLAN-TAMOXIFEN IF:**

- You have ever had any unusual or allergic reaction to MYLAN-TAMOXIFEN or to any one of its ingredients (See What Does MYLAN-TAMOXIFEN Contain?).
- You are pregnant.

MYLAN-TAMOXIFEN should not be given to children.

**PROPER USE OF THIS MEDICATION**

*Use this medication only as directed by your doctor.* Do not use more or less of it and do not use it more often than your doctor ordered. Taking too much may increase the chance of side effects, while taking too little may not improve your condition.

Tamoxifen citrate sometimes causes nausea and vomiting. However, it may have to be taken for several weeks or months to be effective. Even if you begin to feel ill, *do not stop using this medicine without first checking with your doctor.* Ask your health care professional for ways to lessen these effects.

Missed dose - If you miss a dose, take the dose as soon as you remember. Do not take two doses at the same time.

**For management of a suspected drug overdose, contact your regional Poison Control Centre Immediately.**

### **TO STORE THIS MEDICINE**

- KEEP OUT OF THE REACH OF CHILDREN.
- Store at room temperature (15°C to 30°C) and keep away from direct light.
- Do not store in damp places. Heat or moisture may cause the medicine to break down.
- Do not keep outdated medicine or medicine no longer needed.

### **PRECAUTIONS WHILE USING THIS MEDICINE**

It is important to use some type of birth control while you are taking MYLAN-TAMOXIFEN. Please see your doctor for advice on what contraceptive precautions you should take, as some may be affected by MYLAN-TAMOXIFEN. Tell your doctor right away if you think you have become pregnant while taking this medicine or within two months of stopping it.

Driving and using machines: MYLAN-TAMOXIFEN tablets are unlikely to affect your ability to drive a car or to operate machinery. However, tiredness and weakness have been reported with the use of tamoxifen and caution should be observed when driving or operating machinery while such symptoms persist.

### **SIDE EFFECTS OF THIS MEDICINE**

Along with its needed effects, a medicine may cause some unwanted effects. Some side effects will have signs or symptoms that you can see or feel. Your doctor will watch for others by doing certain tests.

Also, because of the way this medicine acts on the body, there is a chance that it might cause other unwanted effects that may not occur until months or years after the medicine is used. Tamoxifen citrate has been reported to increase the risk of cancer of the endometrium or uterus (womb) as well as uterine fibroids (non-cancerous tumours) in some women taking it. It may also cause a drop in some of your blood cell counts, thrombocytopenia (bruising), an increased risk of blood clots and stroke, hypertriglyceridemia, pancreatitis, jaundice and ovarian cysts. In addition, tamoxifen citrate has been reported to cause cataracts and other eye problems. Discuss these possible effects with your doctor.

Check with your doctor or pharmacist as soon as possible if any of the following side effects occur:

- Hot flushes
- Discomfort in the pelvis
- Vaginal bleeding

- Itching around the vagina
- Vaginal discharge
- Stomach upsets (including nausea, vomiting, diarrhea and constipation)
- Headaches
- Light-headedness
- Sensory changes (including taste disorder and numbness or tingling in the skin)
- Fluid retention (possibly seen as swollen ankles)
- Low platelet counts (thrombocytopenia)
- Low white blood cell counts (leucopenia) or decrease of specific white cells (neutropenia and agranulocytosis)
- Decrease in red blood cells (anemia)
- Pain or tenderness in upper abdomen
- Skin rash or itching or peeling skin
- Inflammation of small blood vessels in the skin leading to skin rash
- Hair loss
- Changes in blood tests of liver function. On occasion more severe liver diseases have occurred from which some patients have died. These liver diseases include inflammation of the liver, liver cirrhosis, liver cell damage, formation of fatty liver cells, reduced bile formation, and failure of the liver. Symptoms may include a general feeling of being unwell, with or without jaundice (yellowing of the skin and eyes)
- Disturbances of vision or difficulties in seeing properly (possibly due to cataracts, change to the cornea or disease of the retina)
- Cases of optic nerve diseases have been reported and, in a small number of cases, blindness has occurred
- Breathlessness and cough (inflammation of the lungs)
- Pain, swelling or redness of the calf or leg which may indicate a blood clot

- Chest pain or shortness of breath which may indicate a blood clot
- Leg cramps
- Muscle pain
- Non-cancerous mass in the inner lining of the vagina (called vaginal polyp)
- Inflammation of the skin characterized by rash or erythema, very often on areas exposed to light (a condition called cutaneous lupus erythematosus)
- A skin condition characterized by skin blisters in areas exposed to the light (a condition called porphyria cutanea tarda)
- Sudden onset of weakness or paralysis of the arms or legs, sudden difficulty walking or talking, difficulty in holding things or difficulty in thinking, any of which may occur because the blood supply in the blood vessels of the brain is reduced (these could be symptoms of a stroke)
- At the beginning of treatment, a worsening of the symptoms of your breast cancer such as an increase in pain and /or an increase in the size of the affected tissue may occur. In addition if you experience excessive nausea, vomiting and thirst, you should tell your doctor. This may indicate possible changes in the amount of calcium in your blood and your doctor may have to do certain blood tests.
- Tiredness and weakness

Other side effects not listed above may also occur in some patients. If you notice any other effects, check with your doctor.

**STOP TAKING MYLAN-TAMOXIFEN and contact your doctor immediately in any of the following situations:**

- **If you develop difficulty in breathing with or without swelling of the face, lips, tongue and/or throat.**
- **If you develop swelling of the face, lips, tongue and/or throat which may cause difficulty swallowing.**
- **If you develop swelling of the hands, feet or ankles.**
- **If you develop ‘nettle rash’ or ‘hives’ (urticaria).**

**If you need any further information ask your doctor or pharmacist.**

**You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:**

**1. Report online at: [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect)**

**2. Call toll-free at: 1-866-234-2345**

**3. Complete a Canada Vigilance Reporting Form and:**

**- Fax toll-free to: 1-866-678-6789, or**

**- Mail to: Canada Vigilance National Office**

**Health Canada**

**Postal Locator 0701E**

**Ottawa, ON K1A 0K9**

**Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at [www.healthcanada.gc.ca/medeffect](http://www.healthcanada.gc.ca/medeffect)**

***Note: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.***

This document can be found at: [www.mylan.ca](http://www.mylan.ca).

The full Product Monograph prepared for health professionals can be obtained by contacting the sponsor, Mylan Pharmaceuticals ULC at: 1-800-575-1379

This leaflet was prepared by Mylan Pharmaceuticals ULC  
Etobicoke, Ontario M8Z 2S6

Revised on: February 6, 2014




Mylan Pharmaceuticals ULC  
Etobicoke, ON M8Z 2S6  
1-800-575-1379  
[www.mylan.ca](http://www.mylan.ca)

## PHARMACEUTICAL INFORMATION

### Chemistry

MYLAN-TAMOXIFEN (tamoxifen citrate) is the trans-isomer of a triphenylethylene derivative. The chemical name is (Z)-2-[4-(1,2-diphenyl-1-butenyl) phenoxy]-N,N-dimethyl ethanamine-2-hydroxy-1,2,3-propanetricarboxylate (1:1).

### Chemical Structure



Tamoxifen citrate is an essentially odourless, fine, white crystalline powder. It has a melting point range of 142.0-144.5° C and is photosensitive and hygroscopic.

**Molecular Formula:** C<sub>32</sub>H<sub>37</sub>NO<sub>8</sub>

**Molecular Weight:** 563.62 g/mol

### **Composition:**

Each tablet contains 10 mg or 20 mg of tamoxifen (base) as the citrate salt. MYLAN-TAMOXIFEN tablets also contain mannitol, maize starch, sodium croscarmellose, and magnesium stearate.

### **Storage Conditions:**

MYLAN-TAMOXIFEN should be stored at room temperature (15°C to 30°C) and protected from light.

## PHARMACOLOGY

### Bioavailability:

#### Comparative Bioavailability Studies

A single-dose, two-way crossover bioequivalence study in sixteen (16) healthy adult male volunteers was conducted comparing the 20 mg strength of Nolvadex and Mylan's tamoxifen citrate tablets under fasted conditions.

<b>Tamoxifen (2 x 20 mg) From measured data</b>
<b>Geometric Mean Arithmetic Mean (CV %)</b>

Parameter	Test*	Reference**	% Ratio of Geometric Means	90% Confidence Interval
AUC <sub>T</sub> (ng*hr/mL)	3315.2 3406.4 (22.55)	3364.3 3512.6 (31.30)	98.54%	91.46% - 106.17%
AUC <sub>I</sub> (ng*hr/mL)	3975.4 4031.4 (16.79)	4163.5 4349.5 (30.67)	97.26%	86.60% - 109.24%
C <sub>MAX</sub> (ng/mL)	68.44 69.01 (13.29)	66.73 68.15 (22.84)	102.56%	96.51% - 108.98%
T <sub>MAX</sub> <sup>§</sup> (h)	4.00 (3.00 – 8.00)	4.00 (2.00 – 7.00)		
T <sub>½</sub> <sup>  </sup> (h)	110.3 (37.40)	115.1 (59.76)		

\* Mylan-Tamoxifen, manufactured by Mylan Pharmaceuticals ULC, Canada

\*\* Nolvadex<sup>®</sup> manufactured by AstraZeneca Canada Inc., Canada

§ Expressed as the median (range)

|| Expressed as the arithmetic mean (CV%)

#### Pharmacokinetics and Metabolism

Preliminary pharmacokinetics in women using radiolabeled tamoxifen citrate have shown that most of the radioactivity is slowly excreted in the feces, with only small amounts appearing in urine. The drug is excreted mainly as conjugates, with unchanged drug and hydroxylated metabolites accounting for 30% of the total. Blood levels of total radioactivity following single oral doses of approximately 0.3 mg/kg reached peak values of 0.06-0.14 µg/mL at 3-7 hours after dosing, with only 20-30% of the drug present as tamoxifen citrate. There was an

initial half-life of 7-14 hours with secondary peaks four or more days later. The prolongation of blood levels and fecal excretion is believed to be due to enterohepatic circulation.

### **Antiestrogenic Effect**

In those species in which tamoxifen citrate is an estrogen antagonist, this property is manifest in various ways. Thus in spayed rats, vaginal cornification in response to the daily subcutaneous injection of estradiol can be prevented by concomitant oral dosing with tamoxifen citrate and in immature rats the uterotrophic effect of estrogen can be similarly inhibited.

Also in rats, tamoxifen citrate will terminate early pregnancy by preventing implantation of the blastocysts. It is known that, in rats, estrogen secreted by the ovaries on day 4 of pregnancy initiates implantation (on day 5). There is evidence that, at the lowest dose needed to prevent implantation, tamoxifen citrate acts by counteracting this estrogen. In normal female rats having regular estrous cycles, ovulation can be delayed by administration of a single dose of tamoxifen citrate given on or before the day of diestrus. In the rat (and other spontaneously ovulating species), it appears that the ovulatory discharge of luteinizing hormone (LH) from the pituitary is "triggered" by the action of estrogen on the hypothalamus and/or pituitary. The secretion of estrogen from the ovaries reaches a peak before this LH discharge. The inhibitory effect of tamoxifen citrate on ovulation is attributed to interference with the "feedback" action of estrogen at the hypothalamic and/or pituitary level.

In the pig-tailed monkey (*M. nemestrina*), the activity of tamoxifen citrate as an estrogen antagonist is shown by its effect on the response to estrogen of the perineal region ("sexual skin"). Mature females of this species menstruate regularly at intervals of about 28 days. An edematous swelling of the "sexual skin" develops during the follicular phase of the cycle and subsides more rapidly at about the presumed time of ovulation. The swelling is due to endogenous estrogen and is not seen in the ovariectomized animals unless estrogen is given. In an ovariectomized pig-tail, large daily doses of tamoxifen citrate caused no swelling of the "sexual skin". On the other hand, the swelling induced by daily injection of estradiol was reduced almost to zero by small (oral) doses of tamoxifen citrate given at the same time.

Although the capacity of tamoxifen citrate (demonstrated in spayed rats and monkeys) to inhibit the response to estrogen suffices to explain its effects, outlined above, in intact animals of these species, the possibility that it may also inhibit the endogenous production of estrogen cannot yet be excluded.

In very large doses, tamoxifen citrate causes a limited increase in uterine weight and incomplete vaginal cornification in spayed rats, indicating that it has some degree of estrogenic activity. In one species, the mouse, it behaves as an estrogen without demonstrable estrogen antagonistic activity at any dose.

## **TOXICOLOGY**

Tamoxifen citrate has a low acute toxicity in all species studied, including mice, rats, rabbits, and marmosets. The acute oral LD<sub>50</sub> is greater than 1 g/kg in all species treated.

Chronic toxicity studies were conducted in rats, dogs and marmosets. In the 3 month rat study, tamoxifen citrate was administered daily at doses of 2, 20, and 100 mg/kg as a mixture containing approximately 10% of the corresponding cis-isomer, an estrogen. The changes induced were reduction in weight of ovaries, testes, seminal vesicles, and ventral prostate when related to body weight. Decreased numbers of corpora lutea and follicular cysts, as well as reduction in uterine size, were noted.

The endometrium of all dosed rats showed a complete absence of glands, the epithelium consisting of a single layer of columnar cells with small areas of flattening and occasional squamous metaplasia. The endometrial stroma was somewhat condensed giving it a more fibrous appearance.

High-dose male rats showed cessation of maturation of spermatozoa. Seminiferous epithelium showed scattered necrotic cells. A similar, but less severe change, was seen in males receiving the intermediate dose. The testes in rats which received a low dose showed reduced numbers of spermatocytes and occasional atrophic tubules.

A few treated rats showed a marginal increase in the height of the thyroid epithelium and all treated rats showed a thin zone of adrenal cortical congestion and edema.

In a 6 month rat study tamoxifen citrate was administered orally at doses of 0.05 mg, 0.8 mg, 2.4 mg, 4.8 mg and 9.6 mg/kg. Changes produced by tamoxifen citrate were observed mainly in rats treated with 2.4, 4.8 and 9.6 mg/kg. The reproductive organs showed severe atrophic changes increasing with dose from 2.4 to 9.6 mg/kg. Serum alkaline phosphatase and sodium levels were raised and alanine aminotransferase, aspartate aminotransferase and albumin levels were lowered.

No significant histological findings were observed in the liver.

In a 2 year carcinogenicity study, rats received 5, 20 and 35 mg/kg tamoxifen citrate by gavage (all of which represent significant multiples of the recommended human dose of 20 - 40 mg/day). Hepatocellular carcinomas were reported at all doses. The incidence of these tumours was greater among rats given 20 or 35 mg/kg/day (69%) than those given 5 mg/kg/day (14%). In addition, there appears to be a dose related increase in cataracts.

In the 3 month dog study, doses of 1, 10, and 50 mg/kg were administered orally. The same cis-trans mixture was used as in the 3 month rat study. The treated males in all groups showed a decrease in weight of the testes and pituitary. The females showed an increase in weight of the uterus. Histological observations were as follows:

The testes were atrophic in all dosed dogs. The seminiferous epithelium in most tubules comprised only a layer of spermatogonia and Sertoli cells. There was a considerable increase in the fibrous stroma around the tubules due to the condensation of the normal interstitial tissue as a result of atrophy. This change was attributed to the "estrogenic" effect of the cis-trans mixture.

The ovaries of the dosed females showed reduced numbers of follicles, cessation of ovulation, and hyperplasia of the germinal epithelium. This last change is an exaggeration of the physiological changes seen in metestrus. These changes were less marked in the dogs receiving the lower doses.

In the uterus of all dosed females, there was squamous metaplasia of the endometrium with severe endometritis. The myometrium showed separation of the muscle bundle by a markedly edematous connective tissue which resulted in an "attenuated" appearance of the muscle. However, it was unlikely that there was an alteration in the total bulk of the muscle.

The livers of three males and one female in the highest dosage group showed bile plugs in the bile canaliculi and pigment in the Kupffer cells. The liver was normal apart from slight thinning of the cell cords. These findings are in keeping with the biochemical observation of raised serum alkaline phosphatase. It should be remembered that the dose in this case is 500 times that required to prevent implantation in the dog. All other organs were within normal limits.

Chronic dosing in the marmoset involved one 6 month study. Tamoxifen citrate was administered orally at doses of 0.8, 4.0 and 8.0 mg/kg. The only treatment related, pathologically significant effect due to dosing was the formation of cystically enlarged follicles in the ovaries of the females treated at 8.0 mg/kg.

An additional study of two months duration was conducted in rats where the activity of tamoxifen was compared with that of pure cis-isomer and pure trans-isomer at an oral dose of 20 mg/kg. The reproductive tissue changes were similar to those listed above for all treatment groups, but the adrenal and thyroid lesions were seen only in those rats which received the cis-isomer.

A reversibility test was conducted in female rats using tamoxifen citrate administered orally at doses of 0.5 and 2.0 mg/kg for three months; one-third of the animals were held without drug for an additional three months. Changes similar to those described above were noted in ovaries and uteri after 3-months dosing. These were not present in rats held an additional three months without dosing with tamoxifen citrate.

A reversibility study was conducted in female dogs in which tamoxifen citrate was compared with stilbestrol and clomiphene. Tamoxifen citrate was administered at a dose of 0.1 mg/kg for three months with one animal out of four left untreated for an additional month to test for reversibility.

Squamous metaplasia was not present in the uterus of dogs dosed with tamoxifen citrate. In the myometrium, there was a diminution of collagen with fragmentation of the bundles. The muscle bundles were separated by edema. Withdrawal of tamoxifen citrate produced an

effect similar to a mild estrogenic change with increased collagen in thick bundles. The ovaries showed cessation of ovulation and slight hyperplasia of the germinal epithelium.

The studies comparing tamoxifen citrate with conventional estrogens showed the estrogenic activity of tamoxifen in mice was responsible for gonadal tumours. Chronic studies in mice included an initial 15-month study where the cis-trans mixture described above was administered orally at doses of 5 and 50 mg/kg. This was followed by a 13 month study where the pure cis and trans forms were compared with the cis-trans mixture at a dose of 20 mg/kg and with stilbestrol and ethinyl estradiol. An additional study of 14 months was conducted using a dose of 0.1 mg/kg to investigate the effects of lower doses of the cis, trans, and cis-trans mixture of tamoxifen citrate with stilbestrol and ethinyl estradiol. Interstitial cell tumours of the testes and granulosa cell tumours of the ovary were found and were compound related. After six months of treatment, the mice developed a spinal deformity with kyphosis. The lesion was characterized as elongation of vertebral bodies. In addition, there was increased opacity of long bone due to ossification of the medullary cavity. Some of these can be attributed to estrogenic activity; others were of unknown etiology and did not occur at lower doses.

A series of three tests were conducted to evaluate the ocular toxicity of tamoxifen citrate as compared to compounds which caused ocular lesions and have a similar chemical structure such as clomiphene and triparanol. In the first two tests, female rats were mated and treated with tamoxifen citrate, clomiphene or clomiphene B on day 11 of pregnancy and killed on day 19 or 20. In addition to observations on the uterine and fetal changes, the eyes of the fetuses were examined histologically. In the third experiment, the pregnant females were given clomiphene on day 11 of pregnancy and the fetuses delivered by cesarean section on day 22. They were immediately fostered to control animals and allowed to develop to weaning, when they were killed and examined for cataracts. The results of the first two studies showed no significant increase in embryonic or fetal deaths in any of the treatment groups. Hydramnios was observed in treated rats together with an increase in placental weight and a decrease in uterine weight. Fetal cataracts were observed with clomiphene and clomiphene B, but not with tamoxifen citrate. The incidence of cataracts induced by clomiphene in fostered neonates in the third test was 9.5%.

Teratogenic studies were conducted in rats and rabbits. Since tamoxifen citrate inhibits implantations, some difficulties were encountered in these studies. Doses in rats ranged from 0.02 to 4.0 mg/kg orally and in rabbits from 0.01 to 2.0 mg/kg (administered in the feed). The only drug-induced abnormality which was detected occurred in rats and consisted of a reversible rib deformity which, under certain conditions, had an incidence as high as 50%. Evidence is presented which suggests that the cause of the deformity is mechanical due to the failure of uterine growth caused by the antiestrogenic property of the compound.

Tamoxifen citrate is not mutagenic in a range of *in vitro* and *in vivo* mutagenicity studies.

Tamoxifen citrate was genotoxic in some *in vitro* tests and *in vivo* genotoxicity tests in rodents.

# ESTROGEN RECEPTOR ASSAY

## Introduction

Recently, studies in estrogen-dependent tissues have led to the discovery of a cytoplasmic protein which binds estrogen with high affinity and specificity. Estrogen enters the cytoplasm of all cells whether or not they are estrogen-dependent. However, in the cytoplasm of estrogen-dependent cells are found specific protein molecules that are termed receptors. These receptor proteins bind estrogen biologically with great affinity and specificity. Following this initial binding step, the estrogen receptor complex undergoes an activation which allows the complex to enter the nucleus of the cell and bind to chromatin, the genetic information of the cell. Once bound to the chromatin, the interaction of the estrogen receptor complex with the genetic information of the cell leads to the elaboration of new species of messenger RNA.

These molecules are then released into the cytoplasm where they can be translated on polysomes into new proteins.

Antiestrogens are also able to enter the cytoplasm of the estrogen-dependent cell and bind biologically to the protein receptor with affinity and specificity, thus activating the complex to also translocate to the nucleus. However, the normal estrogen transcriptional processes are altered. Hence, antiestrogens interfere with estrogen-dependent tumour growth by competing with estrogens for the receptor site and by turning off the normal processes of the genetic information within the nucleus. Reports concerning the relationship between clinical responses of patients with breast cancer receiving endocrine therapy and the presence or absence of estrogen receptors have been compiled.

In patients with tumours positive for estrogen receptors, the response rate to endocrine therapy was approximately 56%; and in patients with tumours negative for estrogen receptors, the response rate was about 10%. It was concluded that estrogen receptor assays are useful in predicting the results of endocrine therapy in patients with breast cancer.

## Methods

### a. Dextran-Coated Charcoal Assay (DCC)

The Dextran-Coated Charcoal assay (DCC) involves the extraction of the highly labile estradiol receptor from a cytosol prepared from the tumour tissue. After incubating with tritiated estradiol, which interacts with the binding sites of receptors, the excess estradiol is separated from the incubate with dextran-coated charcoal. The amount of non-specific binding (e.g., albumin) is then determined and the quantity of estradiol receptors in the tissue is estimated from the difference in the total binding less non-specific binding per milligram of protein. Tumours which show binding capacity similar to benign tumours are designated ER-negative, while those with higher binding capacity are designated ER-positive.

## **b. Sucrose Gradient Method (SG)**

The weighed tumour specimen is immersed in liquid nitrogen and shattered. The residual tissue powder is homogenized with efficient cooling in four volumes of buffer, using a tissue disintegrator with two or three homogenization periods, each followed by a cooling period. The homogenate is centrifuged to precipitate the particulate matter. Two portions of the cytosol fraction are removed and treated with either buffer alone or buffer containing an agonist. When equilibrium is reached, tritiated estradiol is added to each mixture. After mixing and standing in the cold, a portion of each mixture is layered on a 10 to 30% sucrose gradient containing buffer, and centrifuged. Successive fractions are collected, from which the radioactivity is counted.

Receptor-positive tumour specimens exhibit 8 S complex, whereas others show various amounts of specific binding in the 4 S region as well. Radioactivity associated with the 8 S form of estrophilin is estimated from the difference in the sedimentation curves, with and without inhibitor, from fraction 1 to the minimum observed around fractions 18 to 22, depending on the ultra-centrifugation. The 4 S radioactivity is similarly calculated by difference of the curves between the minimum and the point where the curve with inhibitor crosses the curve without inhibitor.

### **Interpretation of Results**

Laboratory results of the estrogen receptor assay should be interpreted by a qualified expert, as results may vary due to technique, handling and storage of the specimen, and the patient's menopausal status or recent drug therapy. Quantitative results vary among laboratories and methods. As a result of retrospective correlation made by various investigators based upon patients' response to hormonal manipulation, a result of less than 3 fmol/mg of cytosol protein is considered ER-negative, 3 to 10 fmol/mg cytosol protein is equivocal and over 10 fmol/mg is considered ER-positive.

For more detailed description of the analytic techniques and interpretation of results, the following references may be consulted.

### **ESTROGEN RECEPTOR MONOCLONAL ANTIBODIES**

The quantitative determination of estrogen and progesterone receptors in human breast cancers has served as a guide to therapeutic invention as well as prognosis. Analysis of the receptor content of the primary tumour at the time of mastectomy is able to predict response to endocrine therapy should the tumour recur as well as estimating the probability and rapidity of recurrence. However, current methods for determination of estrogen and progesterone receptors suffer from several deficiencies. They are costly in terms of laboratory time, they require a large sampling of tumour tissue, rapid receptor deterioration during specimen processing or storage can often lead to erroneous results, and ligand-binding assays fail to detect receptor that is already complexed with non-radioactive hormone of endogenous or therapeutic origin. These limitations have led to investigation of improved techniques for a simple, accurate, and inexpensive assay which will recognize the receptor whether or not it retains its ability to bind hormones.

Most recently monoclonal antibody technology has been used to generate a number of monoclonal antibodies specific for antigenic determinants on or near the estrogen receptor site. A number of antibodies have been produced by Greene and Jensen at the Ben May Laboratory for Cancer Research, University of Chicago, Chicago, Illinois.

These specific monoclonal antibodies recognize the extranuclear estrogen receptor of the MCF-7 human breast cancer cell line. These antibodies bind to nuclear and cytosolic estrogen receptors from a variety of tissues and are therefore unique and specific probes for examining the structure and function of the estrogen receptor. Three such antibodies (D58, D75, D547) have been described to recognize different antigenic determinants on the receptor molecule. A combination of two such antibodies can be used in a sandwich technique for the immunoradiometric (IRMA) or enzyme-linked immunosorbent (ELISA) determination of estrogen receptor. These three antibodies recognize estrogen receptors in human breast cancer specimens as well as estrogen receptor in uterine tissue from other species. Further studies with the D547 and D58 monoclonal antibodies have revealed that these antibodies can distinguish among various forms of the estradiol-estrogen receptor complex. The antigenic determinants recognized by these particular antibodies on breast tumour cytosolic receptors are not significantly altered by the binding of either estrogen or antiestrogen to the receptor. Studies such as this are able to demonstrate fundamental differences in the subcellular fate of the estrogen or antiestrogen-receptor complexes, and provide clues to the mechanism of action of estrogens and antiestrogens.

Poulsen has used two monoclonal antibodies specific for MCF-7 estrogen receptor to stain human breast cancer tissue sections using an immunoperoxidase technique. The immunoperoxidase staining was predominantly located in the nucleus of the malignant epithelial cells. No relationship between tumour type or degree of differentiation of invasive ductal carcinomas and staining features was observed. Poulsen found a significant positive correlation between the number of positively stained cells and cytosol receptor content. Similarly, King has developed monoclonal antibody D-5, an IgG<sub>1</sub> which binds to soluble estrogen receptor in a dose-dependent manner. Antibody D-5 is specific for human soluble estrogen receptor and will not react with other steroid-binding proteins or nuclear estrogen receptor. King found a highly significant correlation between estrogen receptor content and D-5 reactivity in human breast cancer sections. Kodama has used similar techniques to study the expression of estrogen receptors of human breast cancer clonal growth using the soft-agar cloning assay. He found that estrogen receptor expression increased with clonal growth of tumour cells to colonies and that estrogen receptor appeared to be expressed in the differentiation process. Finally, Dr. Edwards has developed a monoclonal antibody to the chicken oviduct progesterone receptor. This antibody also recognizes denatured human progesterone receptor as its antigen. Further applications of this monoclonal antibody are currently being examined.

The development of specific monoclonal antibodies directed at antigenic determinants of the estrogen or progesterone receptor will make it possible to more accurately and precisely define levels of estrogen or progesterone receptors in human tumour tissue. This technology will allow such assays to be performed on much smaller amounts of tumour tissue than are currently needed for standard receptor assays. In addition the future availability of standardized kits for

performing monoclonal antibody assays will help provide uniformity when results of receptor levels are described.

## **MONOCLONAL ANTIBODY ESTROGEN RECEPTOR REFERENCES**

Edwards D and McGuire W.

Presentation of monoclonal antibody to progesterone receptor, Workshop on Estrogen and Antiestrogen Action: Basic and Clinical Aspects, Wisconsin Clinical Cancer Center, Madison, WI, June 26-29, 1984.

Greene GL, Fitch FW, and Jensen EV.

Monoclonal antibodies to oestrophilin: probes for the study of oestrogen receptors. Proceedings National Academy of Sciences, USA, 77:157-161, 1980.

Greene GL, Jensen EV.

Monoclonal antibodies as probes for estrogen receptor detection and characterization. J of Steroid Biochemistry, 16:349-353, 1982.

Jensen EV, Greene GL, Hospelhorn VD, and DeSombre ER.

Improved procedures for the determining of oestrogen receptors in breast cancers. Reviews on Endocrine Related Cancer Suppl 9:13-21, 1981.

King RJB, Coffey AI, and Louis K.

Studies with monoclonal antibody raised against partially purified oestradiol receptor from human myometrium, Second International Symposium on Antihormones in Breast Cancer, Berlin, West Germany, October 21-24, 1984, page 24.

Kodama F, Salmon SE, Soehnlen B, and Greene GL.

Expression of estrogen receptor as a clonal marker of differentiation in MCF-7 cells. Am Assoc for Cancer Research, 25:218 (Abstract 863), 1984.

Poulsen HS, Ozzello L, King WJ, Greene GL.

The use of monoclonal antibodies to estrogen receptors for immunoperoxidase detection of ER in human breast cancer, Second International Symposium on Antihormones in Breast Cancer, Berlin, West Germany, October 21-24, 1984, page 25.

Tate AC, DeSombre ER, Greene GL, Jensen EV, and Jordan VC.

Interaction of (3H) estradiol-(3H) monohydroxytamoxifen-estrogen receptor complexes with a monoclonal antibody. Breast Cancer Research and Treatment, 3:267-277, 1983.

## **ESTROGEN RECEPTOR REFERENCES**

Bishop, H.M., Poole, T., Blamey, R.W., Nicholson, R.I. and Griffiths, K.

The importance of rapid freezing of breast tumors for the accurate determination of cytoplasmic oestradiol receptor (ER) status in primary breast cancer. Clin. Oncol. 8(1):86 (1982).

- Chamness, G.C., and McGuire, W.L.  
Scatchard plots: common errors in correction and interpretation. *Steroids*. 26:538-542, 1976.
- Hawkins, R.A., Roberts, M.M. and Forrest, A.P.M.  
Oestrogen receptors and breast cancer: current status. *Brit. J. Surg.* 67(3):153-169 (1980).
- Horwitz, K.B., McGuire, W.L., Pearson, O.H., and Segaloff, A.  
Predicting response to endocrine therapy in human breast cancer: a hypothesis. *Science*. 189:726-727, 1975.
- Layne, E.  
Spectrophotometric and turbidimetric methods for measuring proteins. *Methods Enzymol.* 3:337-454, 1957.
- Leung, B.S., Moseley, H.S., Davenport, C.E., Kippaehne, W.W., and Fletcher, W.S.  
Estrogen receptor in prediction of clinical responses to endocrine ablation. In: W.L. McGuire, P.P. Carbone, and E.P. Vollmer (eds.). *Estrogen Receptors in Human Breast Cancer*, pp. 107-129. New York. Raven Press. 1975.
- Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J.  
Protein measurement with the folin phenol reagent. *J. Biol. Chem.* 193:265-275, 1951.
- McGuire, W.L.  
Current status of estrogen receptors in human breast cancer. *Cancer*. 36:638-644, 1975.
- McGuire, W.L., and De La Garza, M.  
Improved sensitivity in the measurement of estrogen receptor in human breast cancer. *J. Clin. Endocrinol. Metab.* 37:986-989, 1973.
- McGuire, W.L., Pearson, O.H., and Segaloff, A.  
Predicting hormone responsiveness in human breast cancer. In: W.L. McGuire, P.P. Carbone and E.P. Vollmer (eds.). *Estrogen Receptors in Human Breast Cancer*, pp. 17-30, New York: Raven Press, 1975.
- McGuire, W.L.  
Therapeutic significance of hormonal receptor assays. In: *Reviews on Endocrine-Related Cancer*, Proc. Sym. King's College, Cambridge, July 4-5, 1978: Supplement 3, pp. 41-49, 1979.
- Rice, R.H., and Means, G.E.  
Radioactive labeling of proteins in vitro. *J. Biol.Chem.* 246:831-832, 1971.
- Scatchard, G.  
The attraction of proteins for small molecules and ions. *Ann. N.Y. Acad. Sci.* 51:660-672, 1949.

## SELECTED BIBLIOGRAPHY

Anon.

Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. *Lancet* 2(8552):171-175, 1987.

Anon.

Tamoxifen 'promising' for treating breast cancer. *Obstet. Gynecol. News.* 11(3):20 (Feb.) 1976.

Anon.

Two new antiestrogens against breast cancer. *Drug Therapy.* 5:27-30 (Jan.) 1975.

Anon.

Tamoxifen, a new antioestrogen. *Drug Therap. Bull.* 13:19-20 (Feb. 28) 1975.

Anon.

Breast Cancer. Anti-oestrogen therapy, *Nature* 242:88 (Mar. 9) 1973.

Anon.

To counter breast cancer: an oral agent (Abstract), *Med. World News.* 14:52E (Mar. 2) 1973.

Armstrong, E.M. and More, I.A.R.

Ultrastructural demonstration of the mode of action of an antiestrogen (tamoxifen). *Cytobios.* 11:13-16 (Oct.-Nov.) 1974.

Baum, M., et al.

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. *Lancet* 2002; 359: 2131-2139.

Baum, M. Brinkley, D.M., Dosset, J.A., McPherson, K., Jackson, I.M., Rubens, R.D., Smiddy, F.G., Stoll, B.A., Wilson, A.J., Birch, I.H., Palmer, M.K.

Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Analysis at eight years by NOLVADEX® Adjuvant Trial Organisation. *Br J Cancer.* 57:608-611 1988.

Bloom, H.J.G. and Boesen, E.

Anti-oestrogens in treatment of breast cancer: value of nafoxidine in 52 advanced cases. *Brit. Med. J.* 2:7-10 (Apr. 6) 1974.

Braunsberg, H.

Factors influencing the estimation of estrogen receptors in human malignant breast tumors. *Eur. J. Cancer.* 11:499-507 (July) 1975.

Braunsberg, H.

Studies on the effect of anti-oestrogens and dithiothreitol on oestrogen binding by preparations from human breast cancer tissue (Abstract). *Acta Endocrinol. Suppl.* 177:27, 1973.

Brewin, T.B.

Clinical experience with tamoxifen (ICI 46,474) in the management of breast cancer (Abstract B 19). VIII International Congress of Chemotherapy, September 8-14, 1973.

Brewin, T.B.

In-vitro oestrogen sensitivity of breast cancer (Letter). *Lancet.* 1:1339 (June 17) 1972.

Carbone, P.P.

Antiestrogens and breast cancer treatment. *Ann. Intern. Med.* 83(5):730-731 (Nov.) 1975.

Carbone, P.P.

The role of chemotherapy in the treatment of cancer of the breast. *Am. J. Clin. Pathol.* 64(6):774-779 (Dec.) 1975.

Cole, M.P. and Todd, I.D.H.

Tamoxifen (ICI 46,474) - clinical experience in 129 patients with advanced breast cancer. *INSERM.55:245-246*, 1975.

Cole, M.P., Jones, C.T.A., and Todd, I.D.H.

The treatment of advanced carcinoma of the breast with the anti-oestrogenic agent tamoxifen (ICI 46,474) -- a series of 96 patients. *Adv. Antimicrobial Antineoplas. Chemother.* 2:529- 531, 1972.

Cole, M.P., Jones, C.T.A., and Todd, I.D.H.

A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46,474, *Brit. J. Cancer.* 25:270-275 (June) 1971.

Cruickshank, J.

Hormonal effects of the anti-oestrogen agent Nolvadex (tamoxifen). *Aust. N.Z. J. Med.* 6(3):250 (June) 1976.

Dao, T.L., Sinha, D.K. and Patel, J.

Effect of estrogen and progesterone on cellular replication of human breast tumors. *Canc. Res.* 42(1):359-362 (1982).

Engelsman, E., Korsten, C.B., Persijn, J.P., and Cleton, F.J. Anti-oestrogens and breast cancer. *Lancet.* 2:171-172 (July 20)1974.

- Fisher, B., et al.  
Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J Natl Cancer Inst* 1998; 90(18): 1371-1388.
- Fisher, B., et al.  
Treatment of primary breast cancer with chemotherapy and tamoxifen. *N. Eng. J. Med.* 305(1):1-6 (July 2) 1981.
- Fromson, J.M. and Sharp, D.S.  
The selective uptake of tamoxifen by human uterine tissue. *J. Obstet. Gynecol. Brit. Commonw.* 81(4):321-323 (Apr.) 1974.
- Fromson, J.M.  
The metabolism of tamoxifen (ICI 46,474), Part 2: in female patients. *Xenobiotica.* 3(11):711-714, 1973.
- Golder, M.P., Phillips, M.E.A., Fahmy, D.R., Preece, P.E., Jones, V., and Griffiths, K.  
Plasma hormones in patients with advanced breast cancer treated with tamoxifen. *Eur. J. Cancer.* 12(9):719-723 (Sept.) 1976.
- Golder, M.P., Phillips, M.E.A., Baum, A., Griffiths, K., Fahmy, D.R., Henk, J.M., Jones, V., and Preece, P.E.  
Hormones in breast cancer patients on tamoxifen. *Brit. J. Cancer.* 32(2):246-247 (Aug.) 1975.
- Gorins, A. and Eskenazi, F.  
Some new trends in hormone therapy in metastatized breast cancer (in French). *Sem. Hop. Paris Ther.* 51(1):41-43 (Jan.) 1975.
- Gurpide, E.  
Hormones and gynecologic cancer. *Cancer.* 38(1, Suppl.):503-508 (July) 1976.
- Hahnel, R., Twaddle, E., and Ratajczak, T.  
The influence of synthetic anti-estrogens on the binding of tritiated estradiol-17b by cytosols of human uterus and human breast carcinoma. *J. Steroid Biochem.* 4(6):687-695, 1973.
- Henderson, I.C.  
Less toxic treatment for advanced breast cancer. *N. Eng. J. Med.* 305(10):575-576 (Sept. 3) 1981.
- Heuson, J.C., Mattheiem, W.H., Longeval, E., Deboel, M.C., and Leclerq, G.  
Clinical significance of the quantitative assessment of estrogen receptors in breast cancer. *INSERM.* 55:57-70, 1975.

- Heuson, J.C.  
Hormones by administration. Oestrogen antagonists. In: The Treatment of Breast Cancer. H. Atkins, ed. University Park Press, Baltimore, pp. 147-163, 1974.
- Hobbs, J.R., DeSouza, I., Salih, H., and Raggatt, P.  
Selection of hormone-dependent breast cancers. *Brit. J. Surg.* 61(10):785-786 (Oct.) 1974.
- Hobbs, J.R., Newton, K.A., and Westbury, G.C.  
Anti-oestrogens in treatment of breast cancer (Letter). *Brit. Med. J.* 2:500 (June) 1974.
- Hubay, C.A., Pearson, O.H., Marshall, J.S., et al.  
Antiestrogen, cytotoxic chemotherapy, and bacillus calmette-gurin vaccination in stage III breast cancer: a preliminary report. *Surgery.* 87(5):494-501 (May) 1980.
- Hubay, C.A., Pearson, O.H., Marshall, J.S., et al.  
Adjuvant chemotherapy, anti-estrogen therapy and immunotherapy for Stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial. *Cancer.* 46(12):8205-2808 (Dec. 15) 1980.
- Ingle, J.N., Ahmann, D.L., Green, S.J., Edmonson, J.H., Bisel, H.F., Kvols, L.K., Nichols, W.C., Greagan, E.T., Hahn, R.G., Rubin, J., and Frytak, S.  
Randomized clinical trial of diethylstilboestrol versus tamoxifen in postmenopausal women with advanced breast cancer, *N. Eng. J. Med.* 304(1):16-21 (Jan. 1) 1981.
- Jin Y., Desta Z., Stearns V., Ward B., Ho H., Lee K.-H., Skaar T., Storniolo A.M., Li L., Araba A., Blanchard R., Anne Nguyen A., Ullmer L., Hayden J., Lemmler S., Wienshilboum R.M., Rae J.M., Hayes D.F. and Flockhart D.A.  
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment *J Natl Cancer Inst* 97(1) 30-39 (2005)
- Jordan, V.C. and Koerner, S.  
Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. *Eur. J. Cancer.* 11(3):205-206 (Mar.) 1975.
- Jordan, V.C.  
Tamoxifen: mechanism of antitumor activity in animals and man. Abstract of paper presented at the Eastern Cooperative-Oncology Group meeting, Jasper, Alberta. June 22-25, 1974.
- Jordan, V.C.  
The anti-estrogen tamoxifen (ICI 46,474) as an antitumor agent. Abstract of paper presented at the Eastern Cooperative-Oncology Group Meetings, Miami, Florida, Feb. 11-12, 1974.

- Kaiser-Kupfer, M.I. and Lippman, M.E.  
Tamoxifen Retinopathy Cancer Treatment Reports. 62(3):315-320 (Mar.) 1978.
- Kelley BP, Valero V, Yi M, Kronowitz SJ.  
Tamoxifen increases the risk of microvascular flap complications in patients undergoing microvascular breast reconstruction. *Plast Reconstr Surg.* 129(2):305-314 (Feb.) 2012
- Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI et al.  
Selective serotonin reuptake inhibitors and breast cancer mortality in woman receiving tamoxifen: a population based cohort study. *British Medical Journal* 2010;340:c693.
- Krueger DE, Milton RC and Maunder LR.  
The Framingham Eye Study: Introduction to the Monograph, *Survey of Ophthalmology* 24(6):614-620, 1980.
- Kumaoka, S., Takatani, O., Yoshida, M., Miura, S., Takao, T., Hamanaka, Y., Izuo, M., and Okada, T.  
2,3 Epithio-5-androstan-17b-y11-methoxycyclopentyl ether in the treatment of advanced breast cancer - a preliminary clinical trial. *Jap. J. Clin. Oncol.* 6(4):65-68 (June) 1974.
- Legha, S.  
Antiestrogens in the treatment of cancer. *Ann. Intern. Med.* 84(6):751 (June) 1976.
- Lerner, H., Band, P., and Israel, L.  
Treatment of advanced breast cancer with tamoxifen - 10 mg b.i.d. (Abstract C-2). *Proc. Am. Soc. Clin. Oncol.* 17:237 (Mar.) 1976.
- Lerner, H., Band, P. and Israel, B.  
Correlation of estrogen receptor sites to response: report of 11 patients with breast cancer treated with tamoxifen (Abstract 7). *Proc. Am. Assoc. Cancer Res.* 17:2 (Mar.) 1976.
- Lippman, M.E. and Bolan, G.  
Estrogen dependent human breast cancer in continuous tissue culture (Abstract 221). *Endocrinology (Suppl. 96):161*, 1975. Abstract of paper presented at the 57th Annual Meeting of the Endocrine Society, New York, N.Y., June 18-20, 1975.
- Love RR.  
Tamoxifen therapy in primary breast cancer: Biology, efficacy and side effects. *J. Clin Onco.* 7(6)803-815, 1989.
- Lunan, C.B. and Klopper, A.  
Antioestrogens: a review. *Clin. Endocrinol.* 4:551-572 (Sept.) 1975.

- Maass, H., Engel, B., and Trams, G.  
Steroid hormone receptors in human breast cancer and the clinical significance. *J. Steroid Biochem.* 6:743-749 (May) 1975.
- Manni, A., Trujillo, J., and Pearson, O.H.  
Anti-estrogen-induced remissions in stage IV breast cancer (Abstract C-171). *Proc. Am. Soc. Clin. Oncol.* 17:279 (Mar.) 1976.
- Manni, A., Trujillo, J.E., Marshall, J.S., Brodkey, J., and Pearson, O.H.  
Anti-hormone treatment of stage IV breast cancer. *Cancer.* 43(2):444-450 (Feb.) 1979.
- Morgan, L.R., Schein, P.S., Hoth, D., McDonald, J., Posey, L.E., Beazley, R.W., and Trench, L.  
Therapeutic use of tamoxifen in advanced breast cancer: a correlation with biochemical parameters (Abstract 503). *Proc. Am. Assoc. Cancer Res.* 17:126 (Mar.) 1976.
- Morgan, L.R., Posey, L.E., and Trench, L.  
The use of tamoxifen in advanced breast cancer: a correlation with biochemical parameters. *Suppl. to IRCS Med. Sci.* 3(10):26, 1975
- Murphy, L.C., Foo, M.S., Green, M.D., Milthorpe, B.K., Whybourne, A.M., Krozowski, Z.S. and Sutherland, R.L.  
Binding of non-steroidal anti-estrogens to saturable binding sites distinct from the oestrogen receptor in normal and neoplastic tissues. Chapter 19 in "Non-Steroidal Anti-estrogens". Academic Press, Australia, pp. 317-337, 1981.
- Murphy, L.C. and Sutherland, R.L.  
A high affinity intracellular binding site for non-steroidal oestrogen antagonists. *Rev. Endocrine-Related Cancer, Suppl.* 9:177-184 (1981).
- O'Halloran, M.J. and Maddock, P.G.  
ICI 46,474 in breast cancer. *J. Irish Med. Assoc.* 67(2):38-39 (Jan. 26) 1974.
- Palshof, T., Carstensen B., Mouridsen, H.T., and Dombernowsky P.  
Adjuvant endocrine therapy in pre- and post-menopausal women with operable breast cancer. *Rev. Endocrine Related Cancer, Suppl.* 17:43, 1985.
- Pearson, O.H.  
Endocrine treatment of breast cancer. *Ca: Cancer Journal for Clinicians.* 26(3):165-173 (May/June) 1976.
- Pommatau, E., Cheix, F., and Clavel, M.  
Breast cancer treatment by an anti-estrogen (report of 21 cases). *INSERM.* 55:241-244, 1975.

Pritchard, K.I., Thomson, D.B., Myers, R.E., Sutherland, D.J.A., Mobbs, B.G., and Meakin, J.W. Tamoxifen therapy in premenopausal patients with metastatic breast cancer. *Cancer Treat. Rep.* 64(6-7):787-796 (June - July) 1980.

Ribeiro, G. and Swindell, R.  
The Christie Hospital adjuvant tamoxifen trial - status at 10 years. *Br. J. Cancer* 57:601-603, 1988.

Ritchie, G.  
The direct inhibition of prostaglandin synthetase of human breast cancer tumor tissue by 'Nolvadex'. *Rev. Endocrine-Related Cancer, Suppl.* 9:35-39 (1978).

Sasaki, G.H., Leung, B.S., and Fletcher, W.S.  
Therapeutic value of nafoxidine hydrochloride in the treatment of advanced carcinoma of the human breast. *Surg. Gynecol. Obstet.* 142(4):560-564 (Apr.) 1976.

Segaloff, A.  
Hormone treatment of breast cancer. *J. Am. Med. Assoc.* 234(11):1175-1177 (Dec. 15) 1975.

Sponzo, R.W., Barkley, J.M., Horton, J., and Cunningham, T.J.  
Tamoxifen (NSC-180,973) in the management of advanced breast cancer (Abstract 270). *Proc. Am. Assoc. Cancer Res.* 17:68 (Mar.) 1976.

Stearns V., Johnson M.D., Rae J.M., Morocho A., Novielli A., Bhargava P., Hayes D.F., Desta Z. and Flockhart D.A.  
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine *J Natl Cancer Inst* 95(23) 1758-1764 (2003)

Sutherland, R.L., Whybourne, A.M. and Taylor, I.W.  
Cell cycle effects of tamoxifen on MCF 7 human mammary carcinoma cells in culture. *Rev. Endocrine-Related Cancer, Suppl.* 9:169-176 (1981).

Tenni, P., Lalich, D.L. and Byrne, M.J.  
Life threatening interactions between tamoxifen and warfarin. *BMJ* 298:93, 1989.

Tormey, D., Lippman, M., Bull, J., and Myers, C.  
Evaluation of tamoxifen dose in advanced breast cancer (Abstract C-157). *Proc. Am. Soc. Clin. Oncol.* 17:276 (Mar.) 1976.

Ward, H.W.C.  
Anti-oestrogens in treatment of breast cancer (Letter). *Brit. Med. J.* 2:500 (June 1) 1974.

Ward, H.W.C.

Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. *Brit. Med. J.* 1:13-14 (Jan. 6) 1973.

Ward, H.W.C., Arthur, K., Banks, A.J., Bond, W.H., Brown, I., Freeman, W.E., Holme, G.M., Jones, W.G.,

Newsholme, G.A., and Ostrowski, M.J. Anti-oestrogen therapy for breast cancer - a report on 300 patients treated with tamoxifen. *Clin. Oncol.* 4(1):11-17 (Jan.) 1978.

Willis, K.J., London, D.R., and Butt, W.R.

Hormonal effects of tamoxifen in women with carcinoma of the breast. *J. Endocrinol.* 69(3):51P (June) 1976.

Wickerham, L., et al.

Association of Tamoxifen and Uterine Sarcoma (Letter to the Editor). *J. Clin. Oncol.* 20(11):1- 3 (Jan.) 2002

Nolvadex<sup>®</sup>-D Product Monograph. AstraZeneca Canada Inc., Control No.: 167729, Date of revision: November 22, 2013.